Integra LifeSciences Holdings Corporation (IART) is experiencing substantial growth, particularly in its Codman Specialty Surgical (CSS) segment, driven by the increasing demand for its products like Integra Skin and DuraSorb. As of the end of the fourth quarter of 2025, Integra reported a market capitalization of $823.8 million and a net debt of $1.60 billion, with a debt-to-capital ratio at 63.5%. The company is projected to reach revenues of $1.67 billion in 2026, reflecting a 2.2% increase year-over-year.
Despite strong operational momentum, Integra’s financial position is concerning, with cash and equivalents at $264 million and a negative times interest earned ratio of -5.5. Over the past year, stock performance declined by 38.4%, against a 32.9% gain for the S&P 500. The company’s growth is also challenged by macroeconomic factors like inflation and supply chain disruptions, which can impact demand and pricing.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
